Multifaceted approach to determine the antagonist molecular mechanism and interaction of ibodutant ([1-(2-Phenyl-1f-{[1-(tetrahydropyran-4-ylmethyl)- piperidin-4-ylmethyl]-carbamoyl}-ethylcarbamoyl)-cyclopentyl]-amide) at the Human tachykinin NK 2 receptor

Journal of Pharmacology and Experimental Therapeutics

Volumn 329, Issue 2, 2009, Pages 486-495

  Meini, Stefania ^a,b   Bellucci, Francesca ^a   Catalani, Claudio ^a   Cucchi, Paola ^a   Giolitti, Alessandro ^b   Santicioli, Paolo ^a   Giuliani, Sandro ^a  

^a Departments of Pharmacology   (Italy)

^b Menarini Ricerche SpA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE; G PROTEIN COUPLED RECEPTOR; IBODUTANT; ISOLEUCINE; MEN 15596; NEPADUTANT; NEUROKININ 2 RECEPTOR; NEUROKININ A; PHENYLALANINE; PHOSPHATIDYLINOSITOL; RADIOLIGAND; SAREDUTANT; TACHYKININ RECEPTOR ANTAGONIST; TRITIUM; TRYPTOPHAN; TYROSINE; UNCLASSIFIED DRUG; 6 METHYLBENZO(B)THIOPHENE 2 CARBOXYLIC ACID (1 (2 PHENYL ((1 (TETRAHYDROPYRAN 4 YLMETHYL)PIPERIDIN 4 YLMETHYL)CARBAMOYL)ETHYLCARBAMOYL)CYCLOPHENYL)AMIDE; 6-METHYLBENZO(B)THIOPHENE-2-CARBOXYLIC ACID (1-(2-PHENYL-((1-(TETRAHYDROPYRAN-4-YLMETHYL)PIPERIDIN-4-YLMETHYL)CARBAMOYL)ETHYLCARBAMOYL)CYCLOPHENYL)AMIDE; BENZAMIDE DERIVATIVE; CYCLOPEPTIDE; DIPEPTIDE; PHOSPHOLIPASE C; PIPERIDINE DERIVATIVE; THIOPHENE DERIVATIVE;

ANIMAL CELL; ARTICLE; BINDING SITE; CHO CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG COMPETITION; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; FEMALE; HUMAN; KINETICS; LIGAND BINDING; MUTATION; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING; ANIMAL; BINDING COMPETITION; BIOSYNTHESIS; CELL LINE; CHEMICAL STRUCTURE; CHEMISTRY; CRICETULUS; DOSE RESPONSE; HAMSTER; METABOLISM; MOLECULAR CLONING; PROTEIN BINDING; RADIOASSAY;

ANIMALS; BENZAMIDES; BINDING, COMPETITIVE; CELL LINE; CLONING, MOLECULAR; CRICETINAE; CRICETULUS; DIPEPTIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; KINETICS; MODELS, MOLECULAR; PEPTIDES, CYCLIC; PHOSPHATIDYLINOSITOLS; PIPERIDINES; PROTEIN BINDING; RADIOLIGAND ASSAY; RECEPTORS, NEUROKININ-2; THIOPHENES; TYPE C PHOSPHOLIPASES;

EID: 65649121500     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.108.150201     Document Type: Article

References (41)

1. Advenier C, Rouissi N, Nguyen QT, Emonds-Alt X, Breliere JC, Neliat G, Naline E, and Regoli D (1992) Neurokinin a (NK2) receptor revisited with SR 48968, a potent non-peptide antagonist. Biochem Biophys Res Commun 184:1418-1424.
2. Almeida TA, Rojo J, Nieto PM, Pinto FM, Hernandez M, Martin JD, and Candenas ML (2004) Tachykinins and tachykinin receptors: structure and activity relationships. Curr Med Chem 11:2045-2081.
3. Altamura M, Dapporto P, Fedi V, Giolitti A, Guerri A, Guidi A, Maggi CA, Paoli P, and Rossi P (2006) New monocyclic and acyclic hNK-2 antagonists retaining the beta-turn feature: X-ray and molecular modelling studies. Acta Crystallogr B 62:889-896.
4. Audet M and Bouvier M (2008) Insights into signaling from the beta2-adrenergic receptor structure. Nat Chem Biol 4:397-403.
5. Catalioto RM, Criscuoli M, Cucchi P, Giachetti A, Gianotti D, Giuliani S, Lecci A, Lippi A, Patacchini R, Quartara L, et al. (1998a) MEN 11420 (Nepadutant), a novel glycosylated bicyclic peptide tachykinin NK2 receptor antagonist. Br J Pharmacol 123:81-91.
6. Catalioto RM, Cucchi P, Renzetti AR, Criscuoli M, and Maggi CA (1998b) Independent coupling of the human tachykinin NK2 receptor to phospholipases C and A2 in transfected Chinese hamster ovary cells. Naunyn Schmiedebergs Arch Pharmacol 358:395-403.
7. Cheng Y and Prusoff WH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (150) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
8. Cherezov V, Rosenbaum DM, Hanson MA, Rasmussen SG, Thian FS, Kobilka TS, Choi HJ, Kuhn P, Weis WI, Kobilka BK, et al. (2007) High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science 318:1258-1265.
9. 2 receptor antagonist. Eur J Pharmacol 549:140-148.
10. Ciucci A, Palma C, Riitano D, Manzini S, and Werge TM (1997) Glyl66 in the NK1 receptor regulates tachykinin selectivity and receptor conformation. FEBS Lett 416:335-338.
11. Copeland RA, Pompliano DL, and Meek TD (2006) Drug-target residence time and its implications for lead optimization. Nat Rev Drug Discov 5:730-739.
12. 3 receptor. Br J Pharmacol 148:927-937.
13. 3H]SR 48968, a potent nonpeptide radioligand antagonist of the neurokinin-2 receptor. Biochem Biophys Res Commun 191:1172-1177.
14. Fedi V, Altamura M, Catalioto RM, Giannotti D, Giolitti A, Giuliani S, Guidi A, Harmat NJ, Lecci A, Meini S, et al. (2007) Discovery of a new series of potent and selective linear tachykinin NK2 receptor antagonists. J Med Chem 50:4793-4807.
15. Giolitti A, Altamura M, Bellucci F, Giannotti D, Meini S, Patacchini R, Rotondaro L, Zappitelli S, and Maggi CA (2002) Monocyclic human tachykinin NK-2 receptor antagonists as evolution of a potent bicyclic antagonist: QSAR and site-directed mutagenesis studies. J Med Chem 45:3418-3429.
16. Giolitti A, Cucchi P, Renzetti AR, Rotondaro L, Zappitelli S, and Maggi CA (2000) Molecular determinants of peptide and nonpeptide NK-2 receptor antagonists binding sites of the human tachykinin NK-2 receptor by site-directed mutagenesis. Neuropharmacology 39:1422-1429.
17. Giuliani S, Altamura M, and Maggi CA (2008) Ibodutant. Drugs Future 33:111-115.
18. 2 receptor subtype. Eur J Pharmacol 203:365-370.
19. Huang RR, Vicario PP, Strader CD, and Fong TM (1995) Identification of residues involved in ligand binding to the neurokinin-2 receptor. Biochemistry 34:10048-10055.
20. Jaakola VP, Griffith MT, Hanson MA, Cherezov V, Chien EY, Lane JR, Ijzerman AP, and Stevens RC (2008) The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science 322:1211-1217.
21. Kenakin T, Jenkinson S, and Watson C (2006) Determining the potency and molecular mechanism of action of insurmountable antagonists. J Pharmacol Exp Ther 319:710-723.
22. Kenakin TP (1997) Competitive antagonism, in Pharmacologic Analysis of Drug-Receptor Interaction, 3rd ed, pp 331-373, Lippincott-Raven Press Philadelphia, PA.
23. Le MT, Pugsley MK, Vauquelin G, and Van Liefde I (2007) Molecular characterisation of the interactions between olmesartan and telmisartan and the human angiotensin II ATI receptor. Br J Pharmacol 151:952-962.
24. Lecci A and Maggi CA (2003) Peripheral tachykinin receptors as potential therapeutic targets in visceral diseases. Expert Opin Ther Targets 7:343-362.
25. Lindstr̈m E, von Mentzer B, Påhlman I, Ahlstedt I, Uvebrant A, Kristensson E, Martinsson R, Novén A, de Verdier J, and Vauquelin G (2007) Neurokinin 1 receptor antagonists: correlation between in vitro receptor interaction and in vivo efficacy. J Pharmacol Exp Ther 322:1286-1293.
26. 2 receptor to define the binding site of a novel class of antagonists. Eur J Pharmacol 488:61-69.
27. 2 receptor. Eur J Pharmacol 516:104-111.
28. Motulsky HJ and Mahan LC (1984) The kinetics of competitive radioligand binding predicted by the law of mass action. Mol Pharmacol 25:1-9.
29. Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, Fox BA, Le Trong I, Teller DC, Okada T, Stenkamp RE, et al. (2000) Crystal structure of rhodopsin: A G protein-coupled receptor. Science 289:739-745.
30. 2 receptors in human intestine and urinary bladder. Eur J Pharmacol 398:389-397.
31. Porcelloni M, D'Andrea P, Altamura M, Catalioto RM, Giuliani S, Meini S, and Fattori D (2008) Cinnamic acids and mono-substituted benzoic acids as useful capping groups for the preparation of hNK2 receptor antagonists. Bioorg Med Chem Lett 18:4705-4707.
32. Quartara L and Altamura M (2006) Tachykinin receptors antagonists: from research to clinic. Curr Drug Targets 7:975-992.
33. Rasmussen SG, Choi HJ, Rosenbaum DM, Kobilka TS, Thian FS, Edwards PC, Burghammer M, Ratnala VR, Sanishvili R, Fischetti RF, et al. (2007) Crystal structure of the human beta2 adrenergic G-protein-coupled receptor. Nature 450: 383-387.
34. 2 receptor. Biochem Biophys Res Commun 248:78-82.
35. Rosenbaum DM, Cherezov V, Hanson MA, Rasmussen SG, Thian FS, Kobilka TS, Choi HJ, Yao XJ, Weis WI, Stevens RC, et al. (2007) GPCR engineering yields high-resolution structural insights into beta2-adrenergic receptor function. Science 318:1266-1273.
36. Schwartz TW (1994) Locating ligand-binding sites in 7TM receptors by protein engineering. Curr Opin Biotechnol 5:434-444.
37. Sellers DJ, Chappie CR, W Hay DP, and Chess-Williams R (2006) Depressed contractile responses to neurokinin A in idiopathic but not neurogenic overactive human detrusor muscle. Eur Urol 49:510-518.
38. Shukla AK, Sun JP, and Lefkowitz RJ (2008) Crystallizing thinking about the beta2-adrenergic receptor. Mol Pharmacol 73:1333-1338.
39. Sisto A, Altamura M, Cardinali F, D'Andrea P, Rossi C, and Fattori D (2007) α,α-Cyclic amino acids as useful scaffolds for the preparation of hNK2 receptor antagonists. Bioorg Med Chem Lett 17:4841-4844.
40. 2+ mobilization but display similar binding kinetics and identical mechanism of binding in ligand cross-competition. Mol Pharmacol 71:902-911.
41. Vauquelin G and Van Liefde I (2006) Slow antagonist dissociation and long-lasting in vivo receptor protection. Trends Pharmacol Sci 27:355-359.